4Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.Blood, 2001, 97: 1514-1516.
5Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood ,2001, 98: 266-271.
6Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia in pilot report.Blood, 2002, 99:3136-3143.
7Stramba BM,Spagnolo D, Basi G,et al,Are gender differences in QTc present at birth ?Am J Cardial,1995,75:1277-1278.
8Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL):Ⅱ. Clinical efficacy and pharmacokinetics in relapsed patients. Blood,1997, 89: 3354-3360.
9Antzelevitch C,Sicouris Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U wave, triggered activity and torsade de points. J Am Coll Cardiol, 1994,23(3): 259.
10Burashnikov A, Antzelevitch C. Bate-adrenergic stimulation produces transient action potential prolongation in canine ventricular M cells but not in Purkinje. epicardial, or endocardial cell whten contribution of Ik is reduce(abstract) ,PACE, 1996, 19(4):293.
